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Given the increased capacity of countries to produce enormous radioactive catastrophe and the heightened ten-
sions within the political climate, treatment, and prevention of Acute Radiation Syndrome (ARS) is paramount. 
ARS is an understudied disease that describes whole body exposure to high doses of radiation (> 0.7 Gy) in a short 
period of  time1. "e pathophysiology of ARS is characterized by nausea, vomiting, and  diarrhea1. Additionally, 
exposure of (0.7–2 Gy) irradiation leads to a depletion of lymphocytes, granulocytes, and  hepatocytes1,2. "e 
progression of the disease generally follows through three clinically distinct phases. Nausea, headaches, diar-
rhea, fever, altered consciousness, and fatigue characterize the potential outcomes of the initial—prodromal—
response  phase2. During the second, latent phase, the patient displays no symptoms of ARS. "e third stage is 
the manifest illness phase, where the symptoms of ARS become apparent. "ere are currently three existing FDA 
approved treatments for ARS Neupogen, Neulasta, and  Leukine3. However, these approved drugs are not perfect. 
Additional treatment options show some disease-mitigating properties. For instance, the treatment of mice by 
captopril, an angiotensin-converting enzyme (ACE) inhibitor, showed increased survival at thirty days post whole 
body  irradiation4. Additional studies have shown the e#cacy of Insulin-Like Growth factor 1 in mitigating the 
deleterious e$ects of radiation on mice  populations5. However, these treatment methods only address symptoms 
of ARS and require strict dosing protocols to acquire adequate e#cacy. "us, additional treatment options are 
necessary to more e$ectively challenge ARS.
However, ARS is an understudied disease, and the discovery of new treatments faces signi%cant combinatorial 
complexity. To deal with this complexity new treatment options can be elucidated using systems- and network-
based approaches that can help identify critical regulatory genes within the disease state. Weighted Gene Coex-
pression Network Analysis (WGCNA)6 can be used to characterize modules of correlated genes in gene regulatory 
networks. Genes in these modules have high levels of coexpression with a central eigen gene, which represents 
the %rst principal component of a given module. "e central eigen genes have been found to be highly correlated 
to the most connected genes within a module called hubs whose expression levels are representative of highly           ! " # $   % &   ' () *  % '  + *
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correlated genes in the same module. "ese hub genes can be predictive of novel drug targets. For example, such 
analyses have been used to characterize genes and pathways associated with Alzheimer’s  disease7, Schizophrenia 8, 
Amyotrophic Lateral  Sclerosis9, diabetic kidney  disease10, and to determine potential drug targets in  pathogens11, 
and other complex human  diseases12.
To further address challenges with the discovery and development of treatments for complex diseases, repur-
posing of existing drugs to new diseases has become a preferred alternative to elucidating novel drugs due to high 
attrition rate and time. For instance, the FDA-approved radiation countermeasures Neupogen (CSF3R), Neulasta 
(CSF3R), and Leukine (CSF2RA) are repurposed  drugs3. Neupogen and Neulasta are used in chemotherapy-
induced neutropenia and Leukine is used in bone marrow transplant  recipients13.
In this study, we used a network-based systems analysis of %ve transcriptomics datasets obtained under radia-
tion treatment and integrated them with public drug information and disease association. "is led us to predict 
eight targets with repurposable drugs/compounds available.
"e work&ow used to identify drug targets for ARS is shown in Fig. 1. First, we collected ARS relevant data 
from public repositories. Second, we constructed gene coexpression networks from transcriptomics data across 
di$erent species. We used them to identify important genes (hub genes). In the absence of relevant and high-
quality human data, we aimed to identify consensus across the available ARS transcriptomics data for di$erent 
species to maximize the quality of predictions. Using a consensus method increases the likelihood that e#cacy 
in a mouse model would also be observed in human trials, which may minimize the drug development costs. 
Next, to predict potential drug targets for ARS, these hub genes were mapped with external databases of drugs 
and diseases, di$erentially expressed genes under radiation treatments from 6 h to 7 days following radiation of 
0.5–10 Gy (di$erent doses and time). "e human samples were selected from pre and post-irradiation subjects. 
"ese subjects received total body irradiation (TBI) prior to various transplantations. Finally, using literature 
mining, we predicted the drug targets for ARS.
We col-
lected %ve transcriptomics datasets relevant to ARS that were obtained from mice and humans from the GEO 
database. Using these %ve datasets, we constructed %ve weighted gene coexpression networks. A minimum of 28 
Figure 1.  General work&ow to construct gene coexpression network to predict potential drug targets.
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to a maximum of 169 samples was used for network construction (see Materials and methods). "e total num-
ber of genes included in these datasets were between ~ 10,000 to ~ 18,000. "e scale independence within each 
network was achieved using a thresholding power (β) parameter. Across all networks, the selected β was ranging 
from 3 to 20 (Supplementary Data 1). "e number of modules (clusters of genes) identi%ed in each network 
ranged from 5 to 23 (Table 1). Genes in each module in a particular network have the highest topological over-
lap (i.e., robust measure than correlation). "ese genes have signi%cant correlations among expression pro%les 
across di$erent doses of radiation or time points a+er radiation exposure.
In the next step, we 
found the biological signi%cance of modules identi%ed in the constructed networks. Pathway enrichment analy-
sis showed enrichment with biological processes in at least one module across %ve datasets (Supplementary Data 
2). Next, we identi%ed biological processes that were identi%ed by multiple datasets. Among these, 23 gene ontol-
ogy (GO), KEGG, and Reactome terms were enriched in more than one dataset (Fig. 2A). "ese terms included 
biological processes and pathways related to immune response, xenobiotic stimulus, chemical carcinogenesis, 
blood coagulation, and white blood cell activation (Fig. 2B) (P-value < 0.05 and False Discovery Rate < 5%). "e 
highest fold enrichment across all the networks (average fold enrichment) was found in chemical carcinogenesis 
(~ 16 fold), blood coagulation and hemostasis (~ 8 fold), and response to xenobiotic stimuli (~ 7 fold).
In the constructed networks, intramodular connectivity 
was used as a measure to identify hub genes (see Materials and methods). Because of the limited data availability 
of ARS-relevant human data, we identi%ed hub genes that appeared in multiple datasets as high con%dence. To 
select the top hub genes, %rst, we used criteria of maximum overlap of hub genes across the di$erent datasets. We 
identi%ed the top 5, 10, and 20 percent hub genes and compared them across all %ve datasets. In our analysis, the 
top 20% resulted in more hub genes that were overlapped in the maximum number of datasets (Fig. 3A). Among 
Table 1.  Details of constructed gene coexpression networks under radiation treatments.
Species Dataset Number of samples Total number of modules (sub-networks) Total number of genes
Mouse
GSE104121 48 5 18,167
GSE6874 28 10 11,670
GSE10640 169 22 14,835
Human
GSE6874 70 8 12,845
GSE10640 60 23 10,918
Figure 2.  Comparison of enriched biological pathways among di$erent networks. (A) Overlap of the Gene 
Ontology terms (Biological Processes, Molecular Functions, and Cellular Compartments) and pathways (KEGG 
pathways, Reactome pathways, BioCyc) in each network based on 5% False Discovery Rate (FDR). "e venn 
diagram was created using http://bioin forma tics.psb.ugent .be/webto ols/Venn/14 (B) Average fold enrichment of 
biological processes and pathways that were enriched in more than one network.
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these, we found %ve hub genes (Myeloid Cell Nuclear Di$erentiation Antigen (MNDA), Syntaxin 11 (STX11), 
intracellular tyrosine kinase (IKT), Slingshot Protein Phosphatase 2 (SSH2), Keratin 9 (KRT9) ) shared by all 
networks, 58 hub genes shared by four networks, and 412 hub genes that were shared by three networks. On 
the contrary, in both the top 5% and 10% hub genes, no hub genes were shared by all networks. Four networks 
shared only seven genes in the top 10% of hub genes, while not a single hub gen was shared by four out of %ve 
networks in the top 5%. "us, the top 20% cuto$ allowed optimal comparisons amongst the networks.
Next, among the top 20% hub genes (Supplementary Data 3), we chose genes that were identi%ed within 
more than one gene coexpression network. "is analysis resulted in 2,351 hub genes identi%ed within at least 
two coexpression networks (Supplementary Data 3). Enrichment analysis of the selected hub genes showed GO 
biological processes related to leukocyte migration, apoptosis, DNA replication, T cell signaling, NF-κB, and 
IFN-γ signaling (Fig. 3B).
Furthermore, we have investigated the biological processes that are enriched in di$erentially expressed in 
response to high radiation dose (i.e., 10 Gy). Many of the biological processes and pathways related to commonly 
enriched in multiple networks (Fig. 2B) and in hub genes (Fig. 3B) were also enriched in genes upregulated in high 
radiation doses. We found the gene ontology terms regulation of platelet activation (GO:0,010,543; FDR = 0.035), 
blood coagulation (GO:0,007,596; FDR = 0.027), leukocyte di!erentiation (GO:0,002,521, FDR = 0.007), response to 
stimulus (GO:0,050,896; FDR = 0.0003), immune systems process (GO:0,002,376, FDR = 0.0042), cell–cell adhesion 
(GO:0,098,609; FDR = 0.045), intracellular signal transduction (GO:0,035,556; FDR = 0.045), and vesicle-mediated 
transport (GO:0,016,192; FDR = 0.003) as enriched in consistently upregulated genes (upregulated in more sam-
ples than downregulated). A full table of all enriched biological processes is provided as Supplementary Data 4.
To identify drug targets for 
potential drug repurposing, we identi%ed genes that are targets of existing preclinical and FDA-approved drugs 
(Materials and methods) and then selected genes that were di$erentially expressed in response to radiation 
treatments.
Among the identi%ed 2,351 hub genes, 520 genes were mapped with existing preclinical and approved 
drugs/compounds (see Materials and Methods). Next, the selected hub genes were compared with di$erentially 
expressed genes in ARS across 32 conditions (see Materials and Methods). To validate our %ndings, %rst, we 
investigated already known drug targets for ARS that are part of identi%ed hub genes. "e gene target CSF3R of 
two ARS drugs Neulasta and Neupogen appears in our list and they were di$erentially expressed in 21 di$erent 
samples (upregulated in 12 samples and downregulated in 9 samples). Next, we investigated all the hub genes 
for di$erential expression. Of the 520 genes with existing drugs, 293 genes were di$erentially expressed in at 
least eight (25%) of 32 conditions (see Supplementary Data 5). Among these, we identi%ed 81 genes that were 
consistently up-regulated, and 20 genes that were consistently down-regulated (Fig. 4A, Supplementary Data 
5). We then analyzed these 101 di$erentially expressed hub genes with existing drugs and compounds. "ese 
genes include 75 genes involved in (based on Gene Ontology) metabolic processes, 59 genes in response to a 
stimulus, 30 genes in immune system processes, 5 genes in cell population and proliferation, and 4 genes in cell 
signaling (Fig. 4B).
Next, literature mining revealed that 20 (of 101) genes were relevant to the ARS (Table 2). Of these 20 genes, 
we identi%ed eight genes whose response to radiation was incongruent with prognostic favorability (indicated 
with bold font in Table 2): Bromodomain-Containing Protein 4 (BRD4), NF-kB Inhibitor Alpha (NFKBIA)), 
Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A), Tissue Factor Pathway Inhibitor (TFPI), Matrix Metallo-
peptidase 9 (MMP9), Carbonyl Reductase 1 (CBR1), Zeta Chain Of T Cell Receptor Associated Protein Kinase 
70 (ZAP70), and Isocitrate Dehydrogenase (NAD( +)) 3 Beta (IDH3B). A drug and protein target map of selected 
Figure 3.  Identi%cation and analysis of hub genes. (A) top 5%, top 10%, and top 20% hub genes identi%ed for 
each dataset that are identi%ed by %ve, four, three, and two networks. (B) GO biological processes enriched in 
2,351 hub genes with False Discovery Rate < 5%.
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targets is shown in Fig. 5A. Of 20, 11 genes were also consistently upregulated in response to high radiation 
doses (10 Gy and 12 Gy) (Fig. 5B).
"e onset of Acute Radiation Syndrome (ARS) upon exposure to high doses of radiation in a short period is a 
burgeoning problem as access to highly radioactive substances becomes ubiquitous. "us, the importance of 
characterizing and treating this disease is an emerging endeavor. As such, we created gene correlation networks 
to help identify hub genes across multiple transcriptomic data for ARS to identify potential therapeutic options. 
Our transcriptomics-based gene networks were enriched with biological processes, including immune response 
and immune system process that were supported by another  study40. While this study provided an overview 
of potential treatments for ARS there were signi%cant limitations. "e use of multiple species, multiple time 
points and multiple radiation doses means our predictions are a holistic screening of potential treatments for 
ARS. Within the immune response, pathways related to Blood Coagulation and platelet activation, signaling 
and aggregation were enriched processes in the networks. It has been shown previously that coagulopathy and 
lower platelet counts are physiologically-relevant symptoms of acute  radiation32. Identi%cation of genes that have 
been independently shown as relevant to ARS provides partial validation to the constructed networks. Evidence 
was found for eight hub genes identi%ed as potential targets (BRD4, NFKBIA, CDKN1A, TFPI, MMP9, CBR1, 
ZAP70, IDH3B), that altering their expression may induce radioprotective e$ects. "ese eight genes and associ-
ated drugs that have the potential for repurposing are discussed below.
Bromodomain-Containing Protein 4 (BRD4): BRD4 Inhibition was shown to con-
dense chromatin structure and decrease the DNA damage signaling pathway resulting in less DNA repair. Fur-
ther, inhibition of BRD4 demonstrated a relaxation of the chromatin structure and more repair  signalling17. 
"us, inhibition of BRD4 using CPI-0610, a phase two clinical trial molecule, could result in a better prognosis 
for ARS patients. NF-kB inhibitor alpha (NFKBIA): NF-kB inhibition has been shown to increase apoptosis 
through the loss of regulation of the JNK  pathway22. Additionally, increased apoptotic activity is induced by 
 irradiation41. "us inhibition of NFKBIA by Acetylsalicylic acid could increase NF-kB activity and confer an 
antiapoptotic state for the irradiated cells. Cyclin-dependent kinase inhibitor alpha (CDKN1A): It has been 
shown that active and overexpressed CDKN1A increases cell cycle arrest in the G1  phase29. Arrest in this phase 
of the cell cycle was seen in irradiated cells, and cell cycle arrest is a known promoter of  apoptosis30. A preclini-
cal compound GGTI-298 is under investigation that can inhibit CDKN1A. Tissue Factor Pathway inhibitor 
(TFPI): It has been shown that inhibition of TFPI reduces hemophilia bleeding through activating coagulation 
 pathways31. Since hemophilia is an indication of Radiation-Induced Disseminated Intravascular Coagulopathy 
(RDIC) that fresh frozen plasma, platelets or cryoprecipitated antihemophilic factor (AHF) 30. It is possible that 
inhibition of TFPI or its combination with human derived products such as AHF may improve the patients’ 
outcome by mitigating the e$ects of hemophilia in ARS. FDA-approved drug, dalteparin, is an inhibitor avail-
able for TFPI. Matrix Metallopeptidase 9 (MMP9): has been suggested to increase %brosis following  damage42; 
%brosis is increased in cells that receive ionizing  radiation43. Additionally, captopril is an FDA-approved and 
known inhibitor of MMP913 that improves the survival of mice when exposed to high doses of  radiation33. "is 
protection was highly dependent on the timing of the treatment and suggests further time based inquiries of the 
data may elucidate time dependent physiological manifestations of ARS.
Carbonyl Reductase 1 (CBR1) encodes a protein that reduces the level of reac-
tive oxygen species, especially lipid aldehydes. Further, it has been shown that CBR1 confers radioprotectivity to 
Figure 4.  (A) Hub genes found in multiple networks with consistent regulation depicted with the count of 
samples upregulated/downregulated. (B) Count of genes in GO Biological processes amongst 101 consistently 
di$erentially regulated genes.
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head and neck squamous cell  carcinomas35. "us increasing the activity level of CBR1 may decrease the oxida-
tive stress induced by radiation. FDA-approved acetohexamide currently used to treat type II diabetes can be 
used as an activator of CBR1. Zeta Chain of T Cell Receptor Associated Protein Kinase 70 (ZAP70) regulates 
T-cell signaling via interaction with cytoplasmic tyrosine  kinases44. Loss-of-function in ZAP70 has been shown 
to lead to a systemic loss of functional T  cells36 in mice post  radiation37. "us, we hypothesize that upregulat-
ing ZAP70 may lead to regaining functional T cells following radiation. Staurosporine is an experimental drug 
known to modulate the ZAP70 function and could be further explored as a potential repurposing option for 
ARS. Finally, Isocitrate Dehydrogenase (NAD( +)) 3 Beta (IDH3B) facilitates the transfer of Hydrogen from 
Isocitrate to NAD(+); exogenous NADH has been shown to protect mice intestines a+er radiation  injury38. "us, 
we hypothesize that the increase of IDH3B can lead to higher levels of NADH in the system and thus improve the 
prognosis following radiation injury. "e compound coenzyme I (in Phase 2 of clinical trials) is indeed known 
to interact with IDH3B and could be explored for repurposing in ARS.
In addition to the above-discussed genes, all other reported genes elucidate a physiological state that is 
induced under various radiation regiments. We predicted the possible activation of 12 other genes that have 
drugs approved by the FDA or in preclinical and clinical phases. Based on published literature, the activation of 
these genes may have radioprotective properties, and thus the development of corresponding activators may be 
useful. "ese include MYD88 (Myeloid Di$erentiation Primary Response Protein), which is found as upregulated 
in response to radiation and has been found to protect against radiation  injuries16. "e upregulation of Aurora 
Kinase A (AURKA) may also lead to protective properties against radiation as its inhibition has been found to 
increase radiosensitivity in hepatocellular  carcinoma18. Similarly, activation of Protein Tyrosine Phosphatase 
Non-receptor Type 1 (PTPN1) has been found to increase survival in mice a+er irradiation. Finally, Nicotinamide 
N-Methyltransferase (NNMT) has been found to protect cancer cells from radiation.
Further delineation based on timing and dose could further specify which treatment and response best suit 
the target. Additional studies can be conducted to determine the e#cacy of modulating these genes individually 
or in combination. Additionally, the data was garnered primarily from mice which will heavily in&uence the 
predicted treatments. Finally, while this modulation can confer protection against acute radiation syndrome, 
some of these genes can also provide radioprotective properties to tumor cells and hence may not represent a 
long-term treatment option for patients with ARS.
"is study uses systems-level gene associations integrated with multiple biological information levels and pro-
vides a new perspective for the treatment of Acute Radiation Syndrome (ARS). "e study identi%ed eight genes 
with existing drugs and relevance to ARS, which may serve as high con%dence drug target candidates for drug 
repurposing, potentially providing treatment of ARS.
Gene expression datasets  GSE10412145,  GSE1064046, and  GSE687447 related to ARS 
were collected from the GEO  database48. "ese datasets were generated from studies using humans and mice. In 
GSE104121, peripheral whole blood samples were collected from 48 mice following 1–12 Gy total body irradia-
tion (TBI), at 6 h, 16 h, 24 h, and 48 h a+er the treatment. GSE10640 was generated using human and mouse 
samples. Human data were collected prior to and following the total body irradiation (TBI) of patients with 
1.5–2 Gy. From this dataset we used 70 human samples (36 Pre Irradiation 34 post irradiation). "ese samples 
came from 6 h a+er TBI of 1.5–2.0 Gy in preparation for transplantation. "e mouse data were collected fol-
lowing 6 h, 24 h, and 7 days of TBI with 0.5, 2, and 10 Gy. GSE6874 consists of two datasets GSE6871 (human) 
and GSE6873 (mouse). Human data were collected from 60 samples (33 pre-irradiation and 27 post-irradiation) 
pre- and post-irradiated (with 1.5–2 Gy TBI) patients. Mouse data were collected following TBI varied from 
0.5 Gy to 10 Gy.
Di$erential gene expression analysis was conducted for each 
dataset using limma49 and a!y50 R/Bioconductor packages. "e comparison was made between healthy samples 
and the various conditions, including radiation dose and time post-irradiation. Additionally, within GSE10640, 
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Table 2.  Potential drug targets identi%ed for acute radiation syndrome. a "e gene functions were obtained 
from the Uniprot  database39.
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there were multiple species of mice used (Balbc and Blk); hence, di$erential expression was performed between 
healthy Balbc vs. Irradiated and similarly for the Blk mice. A total of 32 comparisons for di$erential expression 
analysis were performed across all %ve datasets (Supplementary Data 5). Two-fold change was considered as a 
signi%cant di$erential expression.
Prior to the construction of the network, data-
sets were quantile normalized using the limma package in R. Next, genes were %ltered based on the coe#cient of 
variation (CV) to remove spurious correlations among genes. A total of %ve networks were constructed consist-
ing of two human (one from GSE10640 one from GSE6874), and three mice networks (GSE10640, GSE6874, 
GSE104121).
Assuming the biological 
networks show scale-free topology, the absolute correlation between genes was raised with a so+ thresholding 
Figure 5.  Drug-target network of potential targets and gene expression. (A) drug-target network. 
PPI = protein–protein associations obtained using STRING database."e network was created using Cytoscape 
version 3.7.215. (B) Fold changes of genes showing consistent di$erential expression of mice in high radiation 
doses (i.e., 10 Gy and 12 Gy) from GSE10640, GSE6874, and GSE104121. Experiment 1 and 2 were from 
BLK mice 24 h post-irradiation with 10 Gy, Experiment 3–6 were from BalbC (3,5,6) and BLK (4) 6hrs post-
irradiation with 10 Gy, and Experiment 7 was performed on BalbC mice 6hrs post-irradiation with 12 Gy.
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power (β) (Supplementary Data 1). All networks were %tted using an R^2 cuto$ of 0.80 6. "e clustering of genes 
was performed based on the dissimilarities of genes using topological overlap measure (TOM). Average Linkage 
Hierarchical clustering was used for module detection in each  network6.
Hub genes were identi%ed in each correlation network characterized by the 
genes with the highest intramodular connectivity  value6. "is value determines the level of module membership 
a gene has; thus, a higher value of intramodular connectivity corresponds to more signi%cant connectivity in the 
module. Genes among the top 20 percent were selected to ensure the highest con%dence in the genes selected 
while simultaneously not introducing false positives by lowering the threshold.
To investigate if a hub gene is an exist-
ing drug target, we used the repurposing  tool51 in the  ConnectivityMap52 and DrugBank  databases13. Addition-
ally, we utilized UniProt 39 and OMIM  databases53 to map genes to associated diseases.
Gene Ontology (GO) biological  processes54, KEGG  pathways55, and 
Reactome  pathways56 terms were utilized for enrichment analysis.
Enrichment of genes within each module in the networks was performed using the  anRichment57 and anRich-
mentMethods packages in R. Pathways with Benjamini–Hochberg (FDR) value < 0.05 were considered to be 
enriched.
A functional analysis of hub genes was performed using  DAVID58,  STRING59 and UniProt databases. In the 
DAVID database and STRING database, biological processes and pathways with FDR < 0.05 were considered 
as enriched.
"e publicly available datasets analyzed during the current study are available in the Gene Expression Omni-
bus. GSE10640 for human and mice irradiated PBMCs—https ://www.ncbi.nlm.nih.gov/geo/query /acc.
cgi?acc=GSE10 640. GSE6874 For human and mice irradiated PBMCs—https ://www.ncbi.nlm.nih.gov/geo/
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